Neurelis Patent-Cliff Exposure & CMS Drug Spending Portfolio

Neurelis (US): 1 reconciled FDA prescription therapies, $162.4M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2042-01-01
2024 CMS Total Public Spend$162.4M
2024 Medicare Part D Spend$24.4M
2024 Medicaid Spend$138.0M
California HCAI SB 17 Filings12 WAC filings (max 18.5% 2-yr change)